The digestive system is an incredibly important part of the body, responsible for breaking down food, absorbing nutrients, and eliminating waste. Unfortunately, digestive health issues are incredibly common, with many people suffering from conditions such as irritable bowel syndrome (IBS), Crohn’s disease, and ulcerative colitis. A medication called Trulance (plecanatide) has been approved by the FDA to help improve digestive health, and this article will discuss how doctors can unlock the benefits of Trulance for their patients.
Trulance is a medication that is used to treat adults with chronic idiopathic constipation (CIC) or irritable bowel syndrome with constipation (IBS-C). It is a guanylate cyclase-C agonist, which means that it helps to stimulate the body’s natural production of a hormone called guanylate cyclase-C, which helps to regulate the digestive system. Trulance works by increasing the amount of fluid in the intestines, which helps to soften stools and make them easier to pass.
Trulance works by stimulating the guanylate cyclase-C receptors in the digestive system. These receptors are responsible for regulating electrolyte and water balance in the intestines. When Trulance stimulates these receptors, it causes the intestines to secrete more fluids, which helps to soften stools and make them easier to pass.
The primary benefit of Trulance is that it can help to improve digestive health by relieving symptoms of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Trulance can help to reduce abdominal pain, bloating, and constipation. It can also help to reduce the frequency of bowel movements, and to improve the consistency of stools.
Trulance is primarily used to treat adults with chronic idiopathic constipation (CIC) or irritable bowel syndrome with constipation (IBS-C). It is important to note that Trulance is not recommended for children under the age of 18, as it has not been studied in this age group. It is also not recommended for pregnant or breastfeeding women, as it has not been studied in this population.
Like all medications, Trulance can cause side effects. The most common side effects of Trulance are abdominal pain, flatulence, diarrhea, nausea, and headache. It is important to note that these side effects are generally mild and do not last long. However, if any of these side effects become severe or persist, it is important to contact a doctor.
Trulance is typically taken once daily, with or without food. The recommended dose for adults is 3 mg once daily. It is important to note that Trulance should not be taken more than once daily, as this could increase the risk of side effects.
Trulance is a medication that is used to treat adults with chronic idiopathic constipation (CIC) or irritable bowel syndrome with constipation (IBS-C). It works by stimulating the guanylate cyclase-C receptors in the digestive system, which helps to increase the amount of fluid in the intestines and soften stools. The primary benefit of Trulance is that it can help to improve digestive health by relieving symptoms of CIC and IBS-C. It is important to note that Trulance is not recommended for children under the age of 18, pregnant or breastfeeding women, or those who take more than the recommended dose. Doctors can unlock the benefits of Trulance for their patients by discussing the potential benefits and side effects of the medication, and providing the correct dosing instructions.
1.
Losing a reward can affect your motivation and performance.
2.
Telemedicine services linked to reducing excess mortality
3.
Study finds 81% of cancer cures touted by TikTok videos are fake
4.
Surgery may not be necessary to treat invasive breast cancer
5.
Patients with head and neck cancer who cannot receive cisplatin now have new hope.
1.
Skin-Sparing Mastectomy: Balancing Cancer Control with Cosmetic Results
2.
Understanding Waldenstrom Macroglobulinemia - A Comprehensive Guide
3.
Exploring the Role of Fecal Leukocytes in Intestinal Health
4.
Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025
5.
Impact of Hormone Therapy Cessation on Tumor Growth: Case Study of Ki-67 Reduction
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
2.
Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment
3.
Oropharyngeal Cancer in Relation to HPV Status
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III
5.
Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation